- Full approval of Covid vaccines in the U.S. may lead to more workplace mandates, Dr. Scott Gottlieb told CNBC on Wednesday.
- But such a move is unlikely to change the minds of people who already don't want the shots, the former FDA chief said.
- "The reality is these vaccines have been used in hundreds of millions of people," he said, adding there's already a robust data set.
Full approval of Covid vaccines in the U.S. may lead to more workplace mandates but is unlikely to change the minds of people who already don't want the shots, Dr. Scott Gottlieb told CNBC on Wednesday.
"There are some for whom this could be a tipping point and it could have more of an incentive to go out and get vaccinated," Gottlieb said on "Squawk Box," referring to the impending authorization of some vaccines by the Food and Drug Administration. "But, I don't think it's going to really drive a lot of additional vaccination among people who have been hesitant so far to be vaccinated."
The FDA has moved up its timetable to fully approve the two-dose Pfizer-BioNTech vaccine, according to The New York Times. The sources who spoke to the Times said the U.S. regulator's unofficial deadline is Labor Day or sooner.
Gottlieb said he would expect the two-shot Moderna vaccine to follow quickly. The only other vaccine cleared for emergency use authorization in the U.S. is Johnson & Johnson's one-dose regimen. J&J has not applied for full approval yet.
The former FDA chief and current Pfizer board member acknowledged many surveys indicate lack of full approval as a reason for vaccine hesitancy. However, he said he doesn't think people care as much as surveyors believe about full approval versus the current EUA status.
"The reality is these vaccines have been used in hundreds of millions of people at this point," Gottlieb said. "You have an enormous data set at this point and the EUA in terms of the review ... really was tantamount to a full BLA, a full biologic license application. So I'm not sure that this is going to make such a distinction in the minds of many consumers."
To combat the spread of the highly transmissible delta variant and encourage immunizations, New York City Mayor Bill de Blasio on Tuesday announced vaccine mandates for a range of indoor venues, which are set to go into effect Aug. 16, with full enforcement beginning in mid-September.
Gottlieb said he supported the move, stressing that packed cities "have to think differently about the risk of spread in congregate settings."
Full FDA approval also gives employers a greater incentive to require vaccinations in the workplace, said Gottlieb, who led the FDA from 2017 to 2019 during Donald Trump's presidency.
Disclosure: Scott Gottlieb is a CNBC contributor and is a member of the boards of Pfizer, genetic testing start-up Tempus, health-care tech company Aetion Inc. and biotech company Illumina. He also serves as co-chair of Norwegian Cruise Line Holdings' and Royal Caribbean's "Healthy Sail Panel."